D.A. Medvedev with Pharma Bio LLC’s Director General V.I. Deigin discussing the company’s innovative products at “Innoforum 2012″.

Our company, Pharma Bio LLC, was founded in 2010 for the purpose of building a modern biotechnology company headquartered in Russia. Our primary area of expertise is production of innovative drugs based on peptides – universal bio-regulators that control almost 80% of biochemical processes in the human body.

One of our main objectives is commercialization of scientific developments in the field of immuno-and neuro-regulators. The company’s leading scientists have been successfully working on complex and highly competitive research in biopharmaceuticals since 1989, occupying leading positions among Russian research centers in biotechnology.

Another research area Pharma Bio LLC is focusing on is development of innovative methods of treatment and prevention of Alzheimer’s disease, one of the most socially significant diseases of the 21st century. We are developing a peptide vaccine designed to protect neurons against beta-amyloid deposits which, according to a leading hypothesis, play a key role in causing Alzheimer’s disease.

Our company was established on the territory and with active participation of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences. We are also an ex-territorial resident of the Skolkovo Foundation, having received this status in December 2010.

The long-term strategic goal of Pharma Bio is to advance Russia’s position on the world biotech stage. Russia’s dependence on imports in the pharmaceutical sector has reached colossal proportions. For example, the annual volume of drugs imported for the treatment of autoimmune diseases is over 2 billion rubles. To reverse the trend of growing imports, Russia needs to foster the creation of domestic  R&D and production centers. One of Russian government’s priorities is modernization and development of the pharmaceutical industry. To this end, the government created the “Pharma 2020″ strategy – a result of collaboration between state bodies and representatives of the pharmaceutical business. The “Pharma 2020″ strategy involves the development of import substitution and creation of a significant amount of original domestic drugs. The work of Pharma Bio should help advance both of these strategic objectives.